US biosimilars savings: $25 billion over 10 years
This article was originally published in Scrip
The US congressional budget office (CBO) predicts that creating a biosimilars approval pathway would save $25 billion in total healthcare spending over a decade. However, this amount is modest compared with estimates highlighted by the generics industry and could undercut arguments that legislation is urgently needed to reduce soaring healthcare costs.
You may also be interested in...
Generic drugs program has approved almost 300 manufacturing changes to help shore up the supply chain, with some prior approval supplements being downgraded to ‘changes being effected’ supplements, FDA officials said at GDUFA III kick-off meeting.
Coronavirus Notebook: Fauci Calls For Restraint In Disclosing Early Data; Bipartisan Lawmakers Want Warp Speed Audit
Dispatches from a world turned upside down also include the conditional approval of remdesivir in South Korea.
US FDA’s ‘may be effective’ standard for granting an emergency use authorization is expected to be comparable to the substantial evidence of effectiveness needed to support full licensure of a COVID-19 vaccine, although EUA allows for a more rapid review, agency officials say.